![Our Pipeline Images Noncore Pro 2 Acumapimod](/media/1qpaec2h/our-pipeline-images_noncore_pro_2_acumapimod.jpg?width=612&height=342&v=1d8320ae0b54ef0)
Acumapimod (BCT197)
For the potential treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD). Acumapimod is an oral p38 MAP kinase inhibitor that has completed Phase 2 development as first-line therapy for severe acute exacerbations of AECOPD. Acumapimod is given during a severe exacerbation to reduce the risk of further exacerbations.
STATUS: Open-to-Partnership